VNI (molecule)
A chemical compound used in antifungal treatments
| Chemical Compound | |
|---|---|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider ID | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Properties | |
| Chemical Formula | |
| Molar Mass | |
| Appearance | |
| Density | |
| Melting Point | |
| Boiling Point | |
| Hazards | |
| GHS Pictograms | [[File:|50px]] |
| GHS Signal Word | |
| GHS Hazard Statements | |
| NFPA 704 | [[File:|50px]] |
| References | |
VNI is a chemical compound that has been studied for its potential use in antifungal treatments. It is known for its ability to inhibit the enzyme lanosterol 14_-demethylase, which is crucial in the biosynthesis of ergosterol, an essential component of fungal cell membranes.
Chemical Structure
VNI is characterized by its complex molecular structure, which includes several functional groups that contribute to its biological activity. The molecule is designed to interact specifically with the active site of lanosterol 14_-demethylase, thereby blocking the synthesis of ergosterol.
Mechanism of Action
The primary mechanism by which VNI exerts its antifungal effects is through the inhibition of lanosterol 14_-demethylase. This enzyme is part of the cytochrome P450 family and plays a critical role in the conversion of lanosterol to ergosterol. By inhibiting this enzyme, VNI disrupts the production of ergosterol, leading to increased membrane permeability and ultimately cell death in fungi.
Research and Development
VNI has been the subject of various studies aimed at evaluating its efficacy and safety as an antifungal agent. Research has shown that VNI is effective against a range of fungal pathogens, including species of Candida and Aspergillus. Its potential use in treating Chagas disease has also been explored, given its ability to inhibit similar enzymes in the causative parasite, Trypanosoma cruzi.
Potential Applications
The development of VNI as a therapeutic agent is ongoing, with studies focusing on its pharmacokinetics, toxicity, and potential for resistance development. Its broad-spectrum activity makes it a promising candidate for treating systemic fungal infections, particularly in immunocompromised patients.
Related Pages
References
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
